Inovio Pharmaceuticals, Inc. (GBM.F)
| Previous close | 10.50 |
| Open | 11.94 |
| Bid | 11.78 x N/A |
| Ask | 11.88 x N/A |
| Day's range | 11.94 - 11.94 |
| 52-week range | 3.77 - 12.14 |
| Volume | |
| Avg. volume | 327 |
| Market cap | 356.051M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2024 and provided an update on recent company developments.
- PR Newswire
INOVIO Reports Inducement Grants Under Inducement Plan
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made equity grants to two newly hired employees under its 2022 Inducement Plan (the "Inducement Plan").
- PR Newswire
INOVIO to Participate in Upcoming Investor Conferences in May
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that management will participate in the following investor conferences during the month of May:
